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ABSTRACT 25 
Hypertension-associated cardiorenal diseases represent one of the heaviest burdens 26 
for current health systems. In addition to hemodynamic damage, recent results have 27 
revealed that hematopoietic cells contribute to the development of these diseases by 28 
generating proinflammatory and profibrotic environments in heart and kidney. 29 
However, the cell subtypes involved remain poorly characterized. Here, we report 30 
that CD39+ regulatory T (TREG) cells utilize an immunosuppression-independent 31 
mechanism to counteract renal and possibly cardiac damage during angiotensin II 32 
(AngII)-dependent hypertension. This mechanism relies on the direct apoptosis of 33 
tissue-resident neutrophils by the ecto-adenosine triphosphate diphosphohydrolase 34 
activity of CD39. Consistent with this, experimental and genetic alterations in TREG/TH 35 
cell ratios have a direct impact on tissue-resident neutrophil numbers, cardiomyocyte 36 
hypertrophy, cardiorenal fibrosis and, to a lesser extent, in arterial pressure elevation 37 
during AngII-driven hypertension. These results indicate that TREG cells constitute a 38 
first protective barrier against hypertension-driven tissue fibrosis and, in addition, 39 
suggest new therapeutic avenues to prevent hypertension-linked cardiorenal diseases. 40 
41 
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INTRODUCTION 42 
Foxp3+CD4+ TREG cells are primarily involved in the negative control of conventional T 43 
cell-dependent immune processes. To this end, they utilize a number of effector 44 
mechanisms including cytokine-dependent paracrine signaling events, interleukin 2 45 
consumption, presentation of immunosuppressive ligands, cytolysis of target cells, and the 46 
modification of cell responses through the degradation of extracellular ATP. This latter 47 
regulatory mechanism is mediated by CD39, an ectoenzyme that displays adenosine 48 
triphosphate diphosphohydrolase activity (1, 2). In addition, they can promote 49 
immunomodulation through the regulation of other hematopoietic cells such as B 50 
lymphocytes, dendritic cells, and macrophages (1, 2). Recent observations have revealed 51 
that tissue-specific TREG subtypes can also exert immunosuppression-independent functions.  52 
The best-characterized examples are TREG cells present in adipose tissue and injured skeletal 53 
muscles that control metabolic indexes and muscle repair, respectively. These TREG subsets 54 
are distinct from those involved in immunosuppression according to T cell receptor 55 
repertoire and transcriptomal features (3, 4). 56 
Hypertension and associated cardiovascular diseases represent nowadays one of the 57 
heaviest burdens for our health systems (5, 6). In addition to the hemodynamic-related 58 
damage inflicted by hypertension itself, a number of pathophysiological circuits that change 59 
the inflammatory, fibrotic, and functional status of peripheral tissues also influence the 60 
progression of these dysfunctions. If untreated, these processes eventually lead to end organ 61 
disease and failure (7, 8). Extensive data indicates that TREG cells play protective roles 62 
against high arterial pressure, cardiovascular remodeling, and heart damage (9-11). The 63 
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exact nature of such protective action is unknown, although it has been commonly assumed 64 
that it was primarily associated with immunosuppression-linked mechanisms. Consistent 65 
with this, a large number of studies have shown that conventional T lymphocytes, the main 66 
cellular targets of TREG cells, do play proactive roles during both the initiation and 67 
progression of hypertension-related pathophysiological events (8, 12-22). The exact T cell 68 
subpopulation(s) involved in those processes is still under debate. Thus, some studies have 69 
proposed the implication of different helper T (TH17, TH1, TH2) subtypes in the engagement 70 
of these pathophysiological responses (13, 16, 17). By contrast, other analyses have 71 
postulated the control of the extent of the hypertensive response is under the regulation of 72 
nonconventional CD3+CD4–CD8– T cell subpopulation that are specifically localized in 73 
perivascular adipose tissue (15). It is possible that these divergent results could reflect the 74 
implication of different T cell subsets in tissue specific pathophysiological responses of the 75 
vasculature, heart, and kidney. Settling this issue is of paramount importance to design new 76 
approaches to combat the inflammatory processes priming cardiorenal fibrosis and, 77 
eventually, end organ disease. In the same context, it is important to clarify the specific role 78 
of TREG cells in the regulation of this complex pathophysiological program and the cellular 79 
targets that are controlled by them. 80 
The Vav family is a group of phosphorylation-dependent GDP/GTP exchange 81 
factors involved in the activation step of Rho proteins. This family has three members in 82 
mammalian species that have been designated as Vav1 (formerly known as Vav or p95vav), 83 
Vav2, and Vav3.  Vav1 is primarily expressed in most hematopoietic lineages whereas 84 
Vav2 and Vav3 show more widespread expression patterns (23-25). Vav1 and, to a lesser 85 
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extent the other family members are important for lymphocyte development, selection, and 86 
effector functions (23-25). Consistent with this, single Vav1–/– and triple Vav1–/–;Vav2–/–87 
;Vav3–/– knockout mice exhibit both peripheral T cell lymphopenia and deficient, T cell 88 
receptor-dependent antigenic responses (26-28). Vav2 and Vav3, but not Vav1, are also 89 
involved in signaling routes contributing to cardiovascular homeostasis. As a consequence, 90 
the single and compound elimination of these two proteins causes hypertension, 91 
cardiovascular remodeling, cardiorenal fibrosis, and renal dysfunctions in mice (29-32).  92 
Based on those observations, we believed that this collection of Vav family knockout mice 93 
could represent a useful tool to clarify obscure aspects of the interplay between the immune 94 
and cardiovascular systems during hypertension. The use of those animals, together with 95 
other experimental mouse models for immunodeficiency and hypertension, allowed us to 96 
discover a hitherto unknown TREG cell-dependent mechanism that controls the extent of the 97 
overall arterial pressure response and end organ dysfunctions during AngII-dependent 98 
hypertension conditions. As we show here, this mechanism is unexpectedly mediated by 99 
the direct, CD39- and apoptosis-mediated homeostatic control of tissue-resident neutrophil 100 
numbers rather than on standard T cell immunosuppression processes. Hence, it is fully 101 
operative even in complete absence of conventional T lymphocytes. This new mechanism 102 
offers potentially interesting therapeutic avenues to prevent cardiorenal fibrosis and ensuing 103 
end-organ disease in patients with long-term, AngII-dependent types of hypertension. 104 
105 
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MATERIALS AND METHODS 106 
Animals. Vav1–/– and Vav2–/–;Vav3–/– mice have been previously described (27, 29, 30). All 107 
Vav family knockout mice were homogenized in the C57BL/10 genetic background. Ly5.1+ 108 
mice were originally obtained from The Jackson Laboratories and maintained at the animal 109 
facility of the Centro de Biología Molecular Severo Ochoa (CSIC, Madrid, Spain). For the 110 
experiments, animals were transferred to the animal facility of the Centro de Investigación 111 
del Cáncer. BALB/c, SCID/Beige (C.B-17/lcrHsd-PrkdcscidLystbg-J), and Foxn1nu mice were 112 
obtained from Harlan Laboratories. For all in vivo studies, animals of the same genotype 113 
were randomly assigned to the different experimental groups. Animals used were either 114 
four- (in the case of analysis of basal conditions) or three-month (in the case of analyses 115 
using osmotic pumps) old. All animal work has been done in accordance with protocols 116 
approved by the Bioethics committees of the University of Salamanca, CSIC, and Centro 117 
Nacional de Investigaciones Cardiovasculares. 118 
 119 
Blood pressure-related analyses. Mean blood pressure was recorded in conscious mice 120 
with the non-invasive tail cuff method (CODA, Kent Scientific). Mice were familiarized 121 
with the procedure during the week previous to data recording to minimize stress-related 122 
blood pressure variations. Blood pressure measurements were always done in the afternoon. 123 
 124 
Histological analyses. Tissues were fixed in 4% paraformaldehyde in phosphate-buffered 125 
saline solution, paraffin-embedded, cut in 2-3 µm sections and stained with hematoxylin 126 
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and eosin (Sigma). Aorta media walls and cardiomyocyte areas were quantified with 127 
MetaMorph software (Universal Imaging). 128 
 129 
Tissue fibrosis determinations. Fibrosis was quantified both immunohistochemically and 130 
biochemically. In the former case, paraffin-embedded tissue sections were stained with 131 
Sirius Red (Fluka). In the latter case, we measured the amount of hydroxyproline present in 132 
tissue lysates. Data from those analyses were converted into amount of collagen by 133 
considering the presence of 12.7% of hydroxyproline residues in that protein. These two 134 
procedures were done as indicated before (29, 30). 135 
 136 
Analysis of kidney function. Mice were placed in metabolic cages and daily urine 137 
production was collected and measured, as indicated before (30). Protein content in urine 138 
was detected with Bradford Protein Assay Reagent (Bio-Rad) using a standard curve of 139 
bovine serum albumin (Sigma).  To calculate creatinine clearance rates, we collected urine 140 
from individual mice for a 24 hour-long period using metabolic cages. In addition, we took 141 
blood samples from animals under study by cardiac puncture to measure the creatinine 142 
concentration in plasma. Urine and plasma creatinine concentrations were determined by a 143 
kinetic colorimetric method using a creatinine assay kit (QuantiChrom™ Creatinine Assay 144 
Kit, BioAssay Systems) according to the manufacturer’s protocol. Creatinine clearance rate 145 
(CCR) was calculated taking into account the urine flow (uf) and concentrations of 146 
creatinine in both urine ([Cre]u) and plasma ([Cre]p) using the formula CCR =  fu × [Cre]u 147 ⁄ [Cre]p. Values were further normalized taking into account the weight of kidneys. 148 
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Determination of mRNA abundance.  RNA was extracted with TRIzol (Sigma) and 149 
quantitative RT-PCR performed with ScriptOne-Step RT-PCR Kit (Bio-Rad) on a 150 
StepOnePlus Real-Time PCR System (Applied Biosystems). Data were analyzed with the 151 
StepOne software v2.1 (Applied Biosystems). Expression of the endogenous mouse P36b4 152 
transcript was used as normalization control. Primers used were 5’-TTG ATG ATG GAG 153 
TGT GGC ACC-3′ (forward for mouse P36b4 cDNA), 5’-GTG TTT GAC AAC GGC 154 
AGC ATT-3′ (reverse for mouse P36b4 cDNA), 5’-CAC CAC GGA CTA CAA CCA GTT 155 
CGC-3’ (forward for mouse Lcn2 cDNA), and 5’-TCA GTT GTC AAT GCA TTG GTC 156 
GGT G-3’ (reverse for mouse Lcn2 cDNA). 157 
 158 
Pharmacological mouse treatments. AngII (1.44 mg/kg/day, Sigma) and ARL67156 (1.1 159 
µg/kg/day, Sigma) were administered for 14 days using osmotic delivery pumps (Model 160 
1002, Alzet) inserted subcutaneously in back of animals. L-NAME (70 mg/100 ml, Sigma) 161 
was administered in the drinking water for four weeks (32). MMF (CellCept, Roche Farma) 162 
was prepared as previously described (33) and administered as indicated in experiments.  163 
 164 
Isolation of hematopoietic cells from tissues. To isolate kidney-infiltrating cells, 165 
anesthetized mice were infused phosphate-buffered saline solution through the heart left 166 
ventricle to eliminate kidney-resident circulating cells. The two kidneys of each mouse 167 
were then collected, decapsulated, cut into small pieces with a sterile scalpel, and incubated 168 
in 10 ml of RPMI containing 10% fetal bovine serum and collagenase (5 mg, Sigma) 20 169 
min at 37 ºC.  After filtering tissue debris, cells were washed twice with phosphate-buffered 170 
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saline solution and resuspended in 8 ml of Roswell Park Memorial Institute (RPMI) media 171 
plus 10% fetal bovine serum. Upon addition of a 5 ml lower layer of Ficoll (Sigma) with a 172 
pipette, samples were centrifuged at 2,000 rpm at room temperature for 10 min.  Cells in 173 
the medium/Ficoll interface were collected using a pipette and counted. To obtain cells 174 
from spleen and thymus, single cell suspensions were obtained by mechanical 175 
homogenization of tissues in 1 ml of phosphate-buffered saline solution supplemented with 176 
2% bovine serum albumin and 0.5 mM EDTA. Bone marrow neutrophils were obtained by 177 
flushing the medullar cavity of isolated femoral bones with phosphate-buffered saline 178 
solution.  In the case of circulating cells, blood samples were collected from hearts with the 179 
aid of heparinized syringes. Cell suspensions obtained in the above conditions were washed 180 
once in phosphate-buffered saline solution, subjected to 0.17 M NH4Cl lysis to eliminate 181 
erythrocytes, and finally washed twice.  Final cell pellets were resuspended in phosphate-182 
buffered saline solution before the immunostaining step. 183 
 184 
Characterization and isolation of hematopoietic cell percentages.  Cell suspensions 185 
obtained as indicated above were stained with combinations of fluorescein isothiochyanate 186 
(FICT)-, allophycocyanin (APC)-, APC-Cy7- or V500-labeled antibodies to CD4 (BD 187 
Biosciences); FITC-, Pacific blue (PB)- or phycoerythrin (PE)-labeled antibodies to CD8 188 
(BD Biosciences); APC- or PE-Cy7-labeled antibodies to CD25 (BD Biosciences); FITC- 189 
or APC-labeled antibodies to Gr1 (eBioscience and BD Biosciences, respectively); APC- or 190 
PE-Cy7-labeled antibodies to F4/80 (eBioscience and BD Biosciences, respectively); PE-191 
labeled antibodies to CD11b (BD Biosciences); PE- or FITC-labeled antibodies to CD11c 192 
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(BD Biosciences); biotin- or APC-labeled antibodies to B220 (BD Biosciences) or PE-Cy7 193 
labeled anti-CD39 (eBioscience). Cell immunolabeling with either FITC- or PE-labeled 194 
antibodies to Foxp3 was done using the Foxp3 Staining Buffer Set (eBioscience). For data 195 
acquisition, samples were collected using a FACSAria III flow cytometer (BD Biosciences) 196 
and blindly analyzed using the FlowJo software (Tree Star).  For in vitro studies, samples 197 
were sorted in sterile condition using a FACSAria III system, collected in phosphate-198 
buffered saline solution supplemented with 50% fetal bovine serum, centrifuged, 199 
resuspended in RPMI (Gibco Life Technologies) supplemented with 10% fetal bovine 200 
serum, 2 mM L-glutamine and antibiotics (100 units/ml Penicillin and 100 µg/ml 201 
Streptomycin, Invitrogen) (referred hereafter as complete media), and cultured in complete 202 
RPMI media as indicated.  203 
 204 
iTREG cell generation. Freshly sorted splenic, CD4+CD25– T cells were plated (1 × 106 205 
cells/ml) onto culture dishes coated with antibodies to mouse CD3 (5 µg/ml, BD 206 
Biosciences) and containing complete RPMI media supplemented with antibodies to CD28 207 
(5 µg/ml, BD Biosciences), transforming growth factor β1 (5 ng/ml, R&D Systems) and 208 
recombinant mouse interleukin 2 (100 IU/ml, Peprotech) for four days. Cells were then 209 
centrifuged, washed twice with phosphate-buffered saline solution, stained with FITC-210 
labeled anti-CD4 (BD Biosciences), APC-labeled anti-CD25 (BD Biosciences), and PE-211 
Cy7-labeled anti-CD39. The iTREG cell population was separated either as a whole 212 
CD4+CD25+ population or fractionated into CD4+CD25+CD39+ and CD4+CD25+CD39– 213 
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populations before being injected into animals. Cells were collected for in vivo experiments 214 
using a FACSAria cell sorter as above. 215 
 216 
TREG injections in mice. iTREG generated as above and freshly sorted splenic CD4+CD25+ 217 
nTREG cells were resuspended in 100 µl of phosphate-buffered saline solution at a cell 218 
density of 2 × 106 cells/ml and injected into the lateral tail vein one day after the 219 
implantation of the drug delivery pumps. Unless otherwise stated, 2 × 105 cells were 220 
injected per animal in these experiments. When indicated, injections were performed with 221 
splenic-derived CD4+CD25– T cells as above.  222 
 223 
Immunodepletion of nTREG cells.  250 µg of either a monoclonal rat antibody to mouse 224 
CD25 (clone PC61.5, eBioscience) or an IgG1Κ isotype negative control (eBioscience) 225 
were injected intraperitoneally one day before the implantation of drug delivery osmotic 226 
pumps.  Extent of immunodepletion achieved in each animal was assessed weekly by flow 227 
cytometry. To that end, blood from anesthetized mice was drawn, cells collected, washed in 228 
phosphate-buffered saline solution, subjected to 0.17 M NH4Cl-mediated erythrocyte lysis, 229 
washed twice with phosphate-buffered saline solution, stained with both FITC-labeled CD4 230 
and APC-labeled CD25, and analyzed by flow cytometry. 231 
 232 
Immunodepletion of neutrophils. WT mice were intraperitoneally injected with either 500 233 
µg of a rat monoclonal antibody to the Ly6G surface marker (clone 1A8, Biolegend) or the 234 
same amount of an IgG1Κ isotype negative control (eBioscience) one day before 235 
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implantation of AngII-delivery osmotic pumps. Percentages of neutrophils in blood were 236 
assessed every three days by flow cytometry using FITC-labeled antibodies to Gr1.  At the 237 
end of experiments, percentages of neutrophils, macrophages, and CD4+ T cells in kidneys 238 
were determined by labeling cells with antibodies to Gr1 (FITC-labeled, eBiosciences), 239 
CD11b (PE-labeled, BD Biosciences), F4/80 (APC-labeled, BD Biosciences), and CD4 240 
(V500-labeled, BD Biosciences). 241 
 242 
Neutrophil recruitment assays.  When indicated, conditioned cell culture supernatants 243 
were obtained from fresh cultures of indicated splenic T cells at 1 x 106 cells/ml. After 72 244 
hours, cells were centrifuged and supernatants collected. For chemotactic assays, 1 x 105 of 245 
freshly purified bone marrow neutrophils were placed onto the upper chamber of a 246 
transwell plate (Corning HTS 24 well transwell, 3.0 µm pore size) that contained in the 247 
lower chamber complete RPMI, cell-conditioned supernatants from indicated cell types 248 
and, when indicated complete RPMI supplemented with 1 µM angiotensin II. 249 
 250 
Determination of ROS production and apoptosis in neutrophil cultures.  Freshly sorted 251 
bone marrow neutrophils were cultured in complete RPMI and treated with 1 µM AngII II 252 
for 20 min. When indicated, cells were pretreated with either 10 µM losartan (Merck) or 10 253 
µM PD123319 (Sigma) for 30 min. 10 µM MMF (CellCept, Roche Farma) was included in 254 
cultures for 120 min before the angiotensin II stimulation. For neutrophil/nTREG cell 255 
coculture experiments, cells sorted as indicated above, treated or untreated with 250 µM 256 
ARL67156 in complete RMPI for 30 min, and then cultured together in same culture media 257 
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for 24 hours always using 1:10 nTREG cell:neutrophil ratios. In some of these experiments, 258 
nTREG cells were either substituted or cocultured with other T cells following the same 259 
experimental procedure. Neutrophil ROS production and apoptosis were assessed using 260 
lucigenine-based chemiluminescence (34) and annexin V/propidium iodide flow cytometry 261 
determinations (35), respectively. The latter assay was done using the Apoptosis Detection 262 
kit from Immunostep. 263 
 264 
Statistics. Data were analyzed with either a two-tailed Student’s t test or a one-way 265 
ANOVA with Bonferroni post hoc test in the case of multiple comparisons. 266 
267 
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RESULTS 268 
Vav proteins are important for hypertension-driven cardiorenal fibrosis 269 
We have reported before that Vav2–/–, Vav3–/–, and Vav2–/–;Vav3–/– (DKO) knockout mice 270 
develop hypertension in an age- and AngII-dependent manner (Fig. 1A) (29, 30, 32). 271 
Further analyses indicated that DKO mice also develop hypertension-linked dysfunctions 272 
similar to those present in the single Vav2–/– and Vav3–/– knockout animals, including the 273 
thickening of the aorta media wall (Fig. 1, B [left panels] and C), hypertrophy of left 274 
ventricle cardiomyocytes (Fig. 1, B [second column from left] and D) and interstitial 275 
fibrosis in both heart (Fig. 1, B [third column from left] and E) and kidney (Fig. 1, B [right 276 
panels] and F). Signs of the latter condition included the detection of collagen with Sirius 277 
red staining (Fig. 1B, third and fourth panels from left) and hydroxyproline tissue content 278 
(Fig. 1, E and F) in both heart and kidney tissue samples. Furthermore, the histological 279 
analyses of kidneys revealed the presence of extensive glomerular sclerosis, necrosis of 280 
distal tubules, and protein casts in kidney sections from DKO mice (Fig. 1G). Consistent 281 
with this, we observed that DKO mice also exhibit alterations in renal physiology such as 282 
reduced flow of urine (Fig. 1H), increased protein content in urine (proteinuria, Fig. 1I), 283 
reduced creatinine clearance rates (Fig. 1J) and increased amounts of the transcript for 284 
lipocalin 2 (Lcn2, Fig. 1K), a well-known early biomarker for both acute and chronic 285 
nephropathies (36). These results led us to investigate the effect of the additional 286 
inactivation of the Vav1 gene in this cardiovascular phenotype using the triple Vav1–/–287 
;Vav2–/–;Vav3–/– knockout (TKO) mouse strain. We found that these mice exhibit 288 
hypertension (Fig. 1A) and vascular remodeling (Fig. 1, B [left panels] and C), although at 289 
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statistically significant lower values than those seen in DKO mice (Fig. 1, A and C). 290 
However, we unexpectedly found that they show no obvious signs of the cardiomyocyte 291 
hypertrophy (Fig. 1, B [second column from left] and D) and cardiorenal fibrosis (Fig. 1, B 292 
[third and fourth columns from left], E and F). They also show normal rates of urine 293 
production (Fig. 1H), urine protein content (Fig. 1I), creatinine clearance (Fig. 1J) and 294 
intrarenal amounts of Lcn2 transcripts (Fig. 1K), further indicating that these mice do not 295 
have any significant signs of heart remodeling and cardiorenal fibrosis in the kidneys.  296 
We surmised that the mild hypertension present in TKO mice could be the cause of 297 
the protection exhibited by these animals against cardiorenal fibrosis and cardiovascular 298 
remodeling. To explore this possibility, we decided to compare the foregoing 299 
pathophysiological parameters in wild-type (WT), DKO and TKO mice under systemic 300 
administration conditions of AngII, a well-known vasoconstriction agent (37). We 301 
speculated that if the above idea were correct, then the chronic delivery of this 302 
vasoconstriction agent had to restore cardiorenal fibrosis and heart remodeling in TKO 303 
mice. To this end, we implanted AngII-delivery osmotic pumps on the backs of WT, DKO 304 
and TKO animals and, subsequently, followed the evolution of blood pressure during a 14 305 
day-long period. In addition, we monitored the rest of cardiovascular and renal parameters 306 
using samples from mice euthanized at the end of AngII treatment. As expected, such 307 
conditions promote the development of high blood pressure (Fig. 1L), renal fibrosis (Fig. 308 
1M), and increased amounts of Lcn2 transcripts in kidneys (Fig. 1N) in WT mice. 309 
Likewise, they exacerbate the hypertensive state of DKO mice (Fig. 1L). However, this 310 
change in arterial blood pressure does not lead to further increases in the already high levels 311 
Fabbiano et al. (2015) 
 16 
of collagen deposition (Fig. 1M) and Lcn2 mRNA expression (Fig. 1N) present in the 312 
kidneys of these mice. The systemic infusion of AngII also aggravates the hypertension 313 
state of TKO mice, although to a lower extent to those found in AngII-infused DKO and 314 
WT mice (Fig. 1L). However, arterial blood pressure does reaches under those conditions 315 
levels comparable to those exhibited by the untreated DKO mice (Fig. 1L) that, as shown 316 
above, do develop cardiorenal fibrosis (Fig. 1, C to K). Despite this, the AngII-treated TKO 317 
mice still do not show any change in renal fibrosis-related parameters (Fig. 1, M and N). 318 
These results suggest that the differences in overall arterial blood pressures could not be the 319 
main leading cause of the different cardiorenal phenotypes exhibited by DKO and TKO 320 
mice. In addition, they indicate that Vav proteins play either direct or indirect roles in 321 
hypertension-driven cardiorenal fibrosis. 322 
 323 
The Vav1 gene deficiency is sufficient to confer protection against tissue fibrosis 324 
To investigate whether the protection exhibited by TKO mice against heart remodeling and 325 
cardiorenal fibrosis was due to the elimination of the three Vav family genes or to the single 326 
inactivation of the Vav1 gene, we next compared the response of control and single Vav1–/– 327 
knockout mice to the systemic administration of AngII. With the exception of the normal 328 
development of vascular remodeling (Fig. 2A), AngII-infused Vav1–/– mice develop no 329 
obvious signs of cardiomyocyte hypertrophy (Fig. 2B), cardiorenal fibrosis (Fig. 2, C and 330 
D) or changes in the expression of the Lcn2 mRNA in kidneys (Fig. 2E). Furthermore, 331 
although AngII-infused Vav1–/– mice initially show elevations in blood pressure similar to 332 
controls (Fig. 2F), they eventually undergo smaller hypertensive responses than WT 333 
Fabbiano et al. (2015) 
 17 
animals at later periods of the systemic administration of AngII (Fig. 2, F and G). The time 334 
of the differential response takes place between the 6th and the 10th day of AngII infusion, 335 
which roughly corresponds to the time in which the cardiorenal fibrosis reaches a plateau in 336 
control mice (Fig. 2H). Thus, the elimination of the Vav1 gene fully recapitulates the 337 
effects derived from the removal of the three Vav family members in this 338 
pathophysiological scenario. Unlike the case of AngII-driven hypertension, we observed 339 
that the Vav1–/– mice are not protected against the dysfunctions under study when treated 340 
with the nitric oxide synthase inhibitor Lω-Nitro-L-arginine methyl ester (L-NAME) (Fig. 341 
2, I to N). This compound promotes hypertension through the blockage of the nitric oxide-342 
mediated dilatation of resistance blood vessels (38). These results suggest that the 343 
antifibrotic protection induced by the Vav1 gene deficiency is not probably due to a 344 
nonspecific, buffering effect on the damaging hemodynamic effects of hypertension on 345 
peripheral tissues. 346 
 347 
Immunosuppressed mice show no resistance to hypertension-linked tissue fibrosis 348 
Vav1–/– and TKO mice, unlike the case of DKO animals, have reduced numbers of 349 
peripheral T cells that, in addition, cannot adequately respond to antigens (26-28). Based on 350 
previous reports indicating that conventional T cells are implicated in the development of 351 
hypertension, tissue fibrosis and end-organ disease (7, 8, 12, 13, 20), we surmised that the 352 
lymphopenic status of those two mouse strains could be the main cause of the resistance 353 
shown to AngII-triggered heart remodeling and cardiorenal fibrosis. If that were the case, 354 
we assumed that a similar phenotype had to be found in other immunocompromised mice. 355 
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In agreement with both this idea and published results (12, 13), we initially found that the 356 
treatment of AngII-infused WT mice with the T cell immunosuppressant mycophenolate 357 
mofetil (MMF)(39) does lead to a hypertensive buffering effect and protection against 358 
cardiorenal fibrosis (SF, data not shown). As an additional control to corroborate these 359 
results, we next decided to analyze the response of Foxn1nu mice, a strain that cannot 360 
generate T lymphocytes due to problems in the development of the thymus, to the infusion 361 
of AngII. Unexpectedly, we found in this case no significant protection against the 362 
cardiorenal fibrosis (Fig. 3, A and B) and a total lack of the hypertension buffering effect 363 
(Fig. 3C) that had been previously seen in Vav1–/– mice. Similar results were obtained with 364 
AngII-treated severe combine immunodeficiency (SCID)/Beige mice that lack both T and 365 
B lymphocytes (SF, data not shown, see also Fig. 7 below). We inferred from these 366 
experiments that T cell immunosuppression per se cannot explain the results obtained with 367 
Vav1–/– and MMF-treated WT mice and, therefore, that other cell types had to be involved in 368 
the development of cardiorenal fibrosis during AngII-triggered hypertension. Concurring 369 
with this idea, we found that MMF also promotes resistance to both cardiorenal fibrosis 370 
(Fig. 3, A and B) and excessive elevations of blood pressure (Fig. 3C) when administered 371 
to AngII-infused Foxn1nu mice. 372 
Taking into account that the Vav1 gene is predominantly expressed in hematopoietic 373 
cells (23), we hypothesized that alterations in cells belonging to either the adaptative or 374 
innate immune had to be involved in the protection against fibrosis exhibited by Vav1–/– 375 
mice. As a first approximation to identify them, we next carried out flow cytometry 376 
determinations to analyze the distribution of a large variety of hematopoietic cell lineages 377 
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in the kidneys, blood, spleens, and thymi from DKO (which showed no cardiorenal 378 
protection), TKO (which exhibited cardiorenal protection), Vav1–/– (normotense and 379 
immunodeficient), and normotense WT mice. We excluded the heart from these studies due 380 
to the difficulty in avoiding crosscontamination from the large numbers of circulating cells 381 
present in that tissue. We found that TKO and Vav1–/– mice have reduced numbers of both 382 
neutrophils and CD4+ cells in kidneys when compared to the other mouse strains (Table 1). 383 
This neutropenia is kidney-specific, because no statistically significant differences are 384 
detected in circulating neutrophils between TKO and DKO mice (Table 1). However, these 385 
two mouse knockout strains do exhibit neutrophilia in the blood when compared to WT and 386 
Vav1–/– animals (Table 1). Whether this is due to their common hypertensive condition 387 
remains unknown. Unlike the case of neutrophils, the CD4+ T cell lymphopenia found in 388 
kidneys of TKO and Vav1–/– mice is also seen in the rest of tissues surveyed (Table 1), a 389 
result consistent with the known intrathymic T cell selection defects present in those mice 390 
(27). Unexpectedly, further flow cytometry analyses revealed that the CD4+ T cell 391 
lymphopenia of TKO and Vav1–/– mice does not apply to CD4+Foxp3+ TREG cells, because 392 
the percentage of these immunoregulatory cells is comparable to those present in WT and 393 
DKO animals in all tissues surveyed (Table 1). By contrast, we observed no statistically 394 
significant variations in the percentages of other hematopoietic lineages surveyed, 395 
including macrophages, CD11c+ and CD11c– dendritic cells, CD8+ T cells, and B 396 
lymphocytes in kidneys of control, DKO, TKO, and Vav1–/– mice (Table 1). These results 397 
suggested that TREG cells, neutrophils or both cell lineages combined could be potentially 398 
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involved in the protection against cardiorenal protection seen in TKO, AngII-infused TKO, 399 
and AngII-infused Vav1–/– mice.  400 
 401 
TREG cells promote protection against hypertension-driven cardiorenal fibrosis 402 
Owing to the above results, we decided to investigate the possible implication of TREG cells 403 
in the protection against hypertension-driven cardiorenal fibrosis shown by Vav1–/– mice. 404 
As a first approximation, we decided to analyze whether the artificial increase in the 405 
TREG/TH ratio in WT mice could reproduce the protection offered by the Vav1 gene 406 
deficiency against cardiorenal fibrosis. To this end, we generated in vitro TREG cells 407 
(referred hereafter as iTREG) by culturing splenic WT CD4+CD25– lymphocytes in the 408 
presence of a differentiation cocktail and, upon purification by flow cytomery (Fig. 4A, 409 
second and third panels from left), injected them into recipient WT mice. We carried out 410 
two independent control experiments to make sure that this approach led to effective 411 
changes in the TREG/TH cell ratio in the recipient mice. Firstly, we confirmed by flow 412 
cytometry that we were actually injecting TREG cells, since ≈80% of the cells differentiated 413 
in vitro were positive for the TREG cell-specific Foxp3 transcriptional factor (Fig. 4A, right 414 
panel). Secondly, by using pilot injection experiments of iTREG cells generated from 415 
C57BL/6 Ly5.1 mice (whose hematopoietic cells are CD45.1+) into WT C57BL/10 mice 416 
(whose hematopoietic cells are CD45.2+), we could estimate that the chosen experimental 417 
protocol does promote a three- and two-fold increase in the total amount of TREG cells in the 418 
recipient mice during the first six and late postinjection days, respectively (Fig. 4B, see plot 419 
with closed boxes). These variations are directly derived from the iTREG cells (CD45.1+) that 420 
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had been injected into mice (Fig. 4B, see plot with open boxes). Moreover, we found that 421 
the injected iTREG population maintains the CD4+CD25+ status during an extended period of 422 
time, although it undergoes a two-fold decrease at the latest time point analyzed (Fig. 4C, 423 
see lanes with light blue boxes). As a result, we calculated that the injected animals 424 
maintain high TREG/nonTREG CD4+ cell ratios during most of the time course used in these 425 
studies (Fig. 4C, compare lanes with light blue and light red boxes). When we repeated 426 
these injection experiments with standard CD57BL/10 iTREG cells, we observed that the 427 
recipient WT mice exhibit no cardiorenal fibrosis (Fig. 4, D and E) and a buffered 428 
hypertensive response (Fig. 4F) upon the systemic administration of AngII. Based on the 429 
results obtained in the analyses of hematopoietic cells present in Vav family knockout mice 430 
(Table 1), we also decided to include as an additional read-out in these studies the 431 
evolution of neutrophil numbers present in the kidneys of iTREG-injected mice. We observed 432 
that these mice show a significant reduction in the percentage of neutrophils in the kidneys 433 
when compared to controls (Fig. 4, G and H), thus suggesting a possible direct link 434 
between the elevated TREG/TH ratios and the kidney neutropenia previously inferred from 435 
the experiments with TKO mice (see above, Table 1). Interestingly, this latter effect is also 436 
observed in mice not treated with AngII (Fig. 4I), possibly indicating a hypertension-437 
independent crosstalk between TREG cells and neutrophils in this tissue. Using a similar 438 
experimental approach, we demonstrated that the expression of Vav1 is not important for 439 
the efficient generation (Fig. 4J) and functionality (Fig. 4K) of iTREG cells in this 440 
experimental setting. Thus, it is unlikely that the phenotype observed in Vav1–/– mice could 441 
be directly caused by the presence of nonfunctional TREG cells in kidneys.  442 
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To further confirm the implication of TREG cells in this process, we next assessed the 443 
effect of eliminating TREG cells in Vav1–/– mice. According to our hypothesis, such a 444 
procedure had to restore fibrosis in the kidneys of these animals and induce a concomitant 445 
increase in the number of intrarenal neutrophils. To achieve this end, we carried out an 446 
immunodepletion strategy consisting in injecting the animals under study with an antibody 447 
to the high affinity interleukin 2 receptor (CD25). As shown in Fig. 5A, this procedure 448 
promotes the efficient and long-term elimination of TREG cells in mice. When infused with 449 
AngII, we observed that TREG-immunodepleted Vav1–/– mice behave like WT mice in terms 450 
of cardiorenal fibrosis development (Fig. 5, B and C) and elevation in blood pressure (Fig. 451 
5D). Importantly, we found that these mice also recover WT-like percentages of kidney-452 
resident neutrophils both under AngII administration (Fig. 5, E and F) and basal (Fig. 5G) 453 
conditions. In addition to further confirm the negative crosstalk between TREG and 454 
neutrophils, these results suggest that the intrakidney neutropenia previously detected in 455 
both AngII-treated and untreated Vav1–/– mice (see above, Table 1 and Fig. 4) cannot be 456 
caused by intrinsic signaling dysfunctions of the Vav1–/– neutrophils. Collectively, these 457 
findings support the idea of a direct functional link between TREG/TH ratios and neutrophil 458 
numbers that, eventually, modulate AngII-driven tissue fibrosis in hypertensive mice. 459 
 460 
Neutrophils contribute to hypertension-driven cardiorenal fibrosis 461 
Given the direct correlation between effective fibrosis development and neutrophil numbers 462 
observed in the foregoing experiments, we next decided to address the direct contribution 463 
of these myeloid cells to this process. To this end, we immunodepleted them in WT mice 464 
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using injections with an antibody (1A8) to the Ly6G subunit of the Gr1 antigen. The 465 
efficient depletion of these cells was confirmed by detecting the percentage of Gr1+ cells in 466 
the blood of injected animals using flow cytometry analyses (Fig. 6A). Using this 467 
approach, we observed that neutrophil-depleted WT mice phenocopy the Vav1 gene 468 
deficiency in terms of protection against cardiorenal fibrosis (Fig. 6, B and C) and 469 
development of mild hypertensive responses (Fig. 6D) when systemically infused with 470 
AngII. This effect is neutrophil-dependent, because the kidneys of the mice pretreated with 471 
the 1A8 antibody exhibit percentages of macrophage (Fig. 6E) and CD4+ T cells (Fig. 6F) 472 
similar to those found in control mice. However, under the same conditions, they show the 473 
expected lack of neutrophils in this organ (Fig. 6, G and H). These results indicate that 474 
neutrophils are critical for the induction of all those AngII-triggered pathophysiological 475 
responses even in fully immunocompetent mice. 476 
 477 
TREG cells protect against hypertension-driven fibrosis in immunodeficient mice 478 
To further rule out that the antifibrotic effect of iTREG cells was independent on their roles in 479 
general T cell immunosuppression, we decided to repeat some of the above experiments in 480 
AngII-infused SCID/Beige (C.B-17/lcrHsd-PrkdcscidLystbg-J) and Foxn1nu mice. SCID/Beige 481 
mice are totally devoid of T and B lymphocytes due to a SCID mutation that impairs the 482 
V(D)J recombination of antigen receptor genes in these two cell lineages. They also have 483 
diminished natural killer cell and macrophage activity owing to the presence of the beige 484 
mutation. As controls for these animals, we used immunocompetent mice of the same 485 
genetic background (BALB/c). Similarly to our results with WT C57BL/10 animals (see 486 
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above, Fig. 4), we observed that the injection of iTREG cells promotes protection against 487 
AngII-induced renal fibrosis in SCID/Beige mice (Fig. 7, A to C), BALB/c (Fig. 7, A to 488 
C), and Foxn1nu mice (Fig. 7, D and E; red bars). These effects are associated with parallel 489 
reductions in the normal percentages of neutrophils present in the kidneys of those animals 490 
(Fig. 7, F to H). As negative control, we did not observe any significant protection upon 491 
the injection of equal numbers of CD4+CD25– lymphocytes into Foxn1nu mice (Fig. 7, D, E 492 
and H; blue bars). Conversely, a similar protection is obtained upon the immunodepletion 493 
of neutrophils (Fig. 7, F and G) in both SCID/Beige and BALB/c mice (Fig. 7, A to C). 494 
Taking into account the above results, we decided to investigate whether the 495 
antifibrotic effects previously observed with the MMF immunosuppressant in the T cell 496 
immunodeficient Foxn1nu strain (Fig. 3) could also involve alterations in either the number 497 
or functionality of neutrophils. We observed that the treatment with this drug does not 498 
induce any significant effect in the neutrophils of Foxn1nu mice under normal conditions. 499 
However, MMF does promote a severe and systemic neutropenic effect when combined 500 
with the administration of AngII (Fig. 7I). Taken together, these findings indicate that the 501 
protective effects observed with the Vav1 deficiency, iTREG cells, and MMF against tissue 502 
fibrosis can be all probably integrated in a common mechanistic framework whose final 503 
end-point is the control of either tissue-resident (in the case of Vav1-deficient and iTREG-504 
inected WT mice) or systemic (in the case of MMF treatments) neutrophil numbers. 505 
Furthermore, they indicate that this TREG/neutrophil axis confers cardiorenal protection 506 
using immunosuppression-independent mechanisms. 507 
 508 
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TREG cells promote direct apoptosis of neutrophils in a CD39-dependent manner 509 
Although our results with both Foxn1nu and SCID/Beige mice excluded the participation of 510 
conventional T cells in this response, they could not formally ruled out the possibility that 511 
other TREG cell partners such as macrophages or dendritic cells could indirectly mediate the 512 
negative effects of TREG cells on neutrophil numbers. Such an idea is, in fact, consistent 513 
with previous findings indicating that TREG cells can mediate both acute lung injury-induced 514 
fibrosis and some pathogen-triggered inflammatory responses by influencing the activity of 515 
non T cell hematopoietic lineages (40, 41). To tackle this issue, we decided to investigate 516 
the effect of TREG cells, AngII and MMF on both neutrophil viability and function using cell 517 
culture experiments. To this end, we first analyzed the effect of coculturing primary bone 518 
marrow neutrophils with splenic CD4+CD25+ T cells that were directly obtained from mice 519 
using flow cytometry purification procedures. These latter cells will be referred to hereafter 520 
as “natural” TREG (nTREG) cells in order to distinguish them from the in vitro-differentiated 521 
iTREG cells used in previous experiments. An example of the purification of these cells can 522 
be found in Figure 8A. These experiments revealed that neutrophils exhibit higher 523 
apoptotic rates when cultured in the presence of nTREG cells (Fig. 8B), an effect that was 524 
independent on the presence of AngII in the culture media (SF, data not shown). Probably 525 
as a result of this apoptotic effect, we also found that the presence of nTREG cells leads to 526 
the elimination of the production of reactive oxygen species (ROS) that is stimulated by 527 
AngII in neutrophils (Fig. 8C). ROS production is mediated by the AngII AT1 receptor in 528 
neutrophils, because this response can be blocked by AT1 (losartan), but not AT2 529 
(PD123319), receptor antagonists (Fig. 8C). Additional experiments indicated that nTREG 530 
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cells are not exclusively involved in the negative regulation of neutrophils. For example, 531 
we observed that the supernatants from nTREG cultures can promote the chemotaxis of 532 
primary neutrophils (Fig. 8D). All these actions seem to be nTREG-specific, because no 533 
significant effects were observed when using TH (CD4+) and cytotoxic (CD8+) T 534 
lymphocytes (Fig. 8, B to D) in these experiments. Thus, similarly to the observations 535 
made in vivo, the present results indicate that TREG cells control in an AngII-independent 536 
manner the viability of primary neutrophils. 537 
TREG cells can inhibit other cell types using a number of signaling mechanisms, 538 
including CTLA4-mediated immunosuppression, granzyme and perforin-dependent 539 
cytotoxicity, cytokine-based paracrine signaling, and the degradation of extracellular ATP 540 
using the ecto-adenosine triphosphate diphosphohydrolase activity of plasma membrane-541 
localized CD39 molecules (1, 2). We ruled out the three former mechanisms, because our 542 
results indicated that the TREG/neutrophil interconnection was probably associated with an 543 
immunosuppression-independent proapoptotic mechanism (see above, Fig. 7 and Fig. 8B). 544 
We also excluded a paracrine-dependent proapoptotic effect, given our observations 545 
indicating that the supernatants obtained from nTREG cell cultures promote the chemotaxis 546 
rather than the apoptosis of neutrophils (Fig. 8D). The foregoing observations led us to 547 
consider the possible implication of CD39, a surface molecule expressed by 50 ± 7% and 548 
58 ± 6 % of the iTREG and splenic nTREG cells used in this work, respectively (n = 4 549 
independent experiments). This percentage is further expanded up to 71.7 ± 4.1% of all the 550 
iTREG population when AngII is added to the in vitro TREG differentiation cocktail (n = 4 551 
independent experiments, P ≤ 0.05). To test this idea, we purified and separated away 552 
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splenic CD39+ and CD39– nTREG cells by flow cytometry (Fig. 8E) and, subsequently, 553 
cultured them with primary bone marrow neutrophils. Using this approach, we observed 554 
that the CD39+ nTREG cell population, but not the CD39– one, prompts the apoptosis of 555 
neutrophils (Fig. 8F). This proapoptotic effect is eliminated when the ATPase activity of 556 
this ectoenzyme is blocked in those cultures with either a CD39 drug inhibitor (ARL67156; 557 
Fig. 8F) or excess of its normal catalytic substrate (ATP; Fig. 8G). As control, no rescue is 558 
observed when the TREG/neutrophil cultures are supplemented with a nonhydrolyzable form 559 
of ATP (adenosine 5’-[γ-thio]triphosphate, Fig. 8G). Consistent with these results, we 560 
found that ARL67156 eliminates the negative effect of nTREG cells on ROS production by 561 
AngII-stimulated neutrophils (Fig. 8C). By contrast, ARL67156 does not block other TREG 562 
cell activities, such as neutrophil chemotaxis (Fig. 8D). ARL57156 (Fig. 8F) and ATP 563 
(Fig. 8G) cannot prevent either the basal apoptotic rates typically exhibited by neutrophils 564 
in cell culture, further confirming that their effects are CD39-dependent.  565 
We next investigated whether the neutropenic effect found in MMF-treated mice 566 
could be the result in some direct action of the drug on primary neutrophils. As shown in 567 
Fig. 8H, MMF has no effect on the viability of these cells under normal culture conditions. 568 
However, it promotes enhanced apoptotic rates when when used in AngII-stimulated 569 
neutrophil cultures (Fig. 8H). This goes in parallel with the elimination of ROS production 570 
by the stimulated neutrophils (Fig. 8I). In agreement with the stimulation-dependent effect 571 
of this drug, its proapoptotic effect is lost when the stimulated neutrophils are pretreated 572 
with losartan but not PD123319 (Fig. 8H). Taken together, these results indicate that the 573 
neutropenia observed in TKO, Vav1–/–, and AngII plus MMF-treated nude mice is probably 574 
Fabbiano et al. (2015) 
 28 
due to a direct proapoptotic cell autonomous effect of both CD39+ TREG cells and MMF on 575 
neutrophils. 576 
 577 
CD39+ TREG cells protect against AngII-driven hypertension and its comorbidities 578 
To corroborate the physiological relevance of the in vitro culture experiments described in 579 
the previous section, we investigated the actual contribution of CD39+ TREG cells to the 580 
cardiovascular and renal parameters under study in this work. To this end, we first decided 581 
to analyze the effect of injecting flow cytometry-purified CD39+ and CD39– iTREG cells 582 
(Fig. 9A) in the AngII-mediated fibrosis of WT mice. We observed that the CD39+ iTREG 583 
subset does promote kidney neutropenia (Fig. 9B), protection against cardiorenal fibrosis 584 
(Fig. 9, C and D), and the expected buffering effect on arterial blood pressure elevation 585 
(Fig. 9E) in the recipient mice. However, such an activity was not observed when using 586 
CD39– iTREG cell-injected WT mice (Fig. 9, B to E). Further underscoring the role of the 587 
CD39 ectoenzyme in this process, we found that the effect induced by the injected CD39+ 588 
iTREG cells is abolished when the recipient mice are treated with ARL57156 (Fig. 9, B to 589 
E). Confirming the implication of these cells in the phenotype shown by knockout mice, we 590 
found that the administration of this CD39 inhibitor to AngII-treated Vav1–/– mice 591 
mimicked the effects of the TREG immunodepletion previously seen in those mice, including 592 
the restoration of increased numbers of kidney-resident neutrophils (Fig. 9F), development 593 
of fibrosis in both the heart (Fig. 9G) and kidneys (Fig. 9H), elevated amounts of Lcn2 594 
mRNA expression in kidneys (Fig. 9I), reductions in creatinine clearance by kidneys (Fig. 595 
9J), and the restoration of a full hypertensive response (Fig. 9K). Collectively, these results 596 
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indicate that TREG cells are involved in the protection against hypertension-driven 597 
cardiorenal fibrosis using a nonconventional, CD39- and neutrophil-dependent mechanism 598 
(Fig. 9L). 599 
600 
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DISCUSSION 601 
Our results have unveiled a hitherto unknown CD39+ TREG cell/neutrophil-based mechanism 602 
that probably represents a first trench of protection against AngII-elicited heart remodeling 603 
and cardiorenal fibrosis (Fig 9L). This mechanism has been found operative under both 604 
normotensia and hypertension conditions, suggesting that it may be involved in the 605 
homeostatic control of neutrophil numbers in some specific tissues. The utilization of a 606 
CD39+ TREG cell/neutrophil axis seems prima facie a good functional strategy to control 607 
these pathophysiological processes, because evidence from other fibrosis-associated kidney 608 
dysfunctions indicates that neutrophils act as critical “decision-shapers” during the 609 
inflammatory-based priming phase of the fibrotic process (8). Furthermore, they are highly 610 
dependent on both extracellular ATP and ADP availability for a large variety of functions, 611 
including survival, chemotaxis, and other proinflammatory-connected functions (42). 612 
Interestingly, this antifibrotic mechanism seems to be quite specific, as it does not confer 613 
protection under L-NAME-triggered hypertension conditions. Since Vav1–/– mice show 614 
increased TREG/TH cell ratios and neutropenia prior to the hypertension step, it is likely that 615 
this differential response could be due to the engagement of different proinflammatory or 616 
profibrotic routes upon the systemic administration of AngII and L-NAME. Likewise, we 617 
have observed that this antifibrotic mechanism does not prevent the arterial remodeling that 618 
typically develops under AngII-driven hypertension conditions. This is consistent with 619 
previous results indicating that this response may involve either macrophages or a 620 
nonconventional CD3+CD4–CD8– T cell subpopulation (15, 20). 621 
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It is worth noting that this new regulatory layer involved in fibrotic responses does 622 
not exclude the participation of TH cells and other myeloid cells further downstream in the 623 
fibrotic pathophysiological cascade. On the contrary, our observations suggest that this first 624 
TREG-dependent barrier of defense against AngII-driven tissue fibrosis is probably 625 
overcome under chronic hypertension conditions by the subsequent recruitment and/or 626 
activation of either TH cell subtypes or downstream proinflammatory responses providing 627 
that normal TREG/TH ratios are preserved in mice (Fig. 9L). In any case, the protection 628 
shown by TREG cell-transplanted WT mice suggests that therapies based on either alterations 629 
of TREG/TH cell ratios (i.e., via either allogenic TREG cell transfer or in vivo expansion of 630 
TREG cells) or ATP/ADP depletion-dependent reduction of neutrophil numbers (i.e., using 631 
recombinant CD39 delivery techniques) could be valuable, either singlehandedly or in 632 
combination with AngII route inhibitors, to prevent cardiorenal fibrosis and the ensuing 633 
end-organ disease in patients with AngII-dependent hypertension. 634 
Our results also suggest that previous findings regarding the positive effect of MMF 635 
and other immunosuppressants in hypertension-driven fibrosis (12, 13, 21) can be 636 
explained by the enhancement of this TREG-dependent mechanism. Consistent with this, it 637 
has been shown that some of those immunosupressants promote the peripheral expansion of 638 
TREG cells (43, 44). The mechanism reported here could be also involved in both the fibrotic 639 
and hypertensive effects induced by either the transplantation and depletion of both 640 
conventional T and TREG cells due to the changes in TREG/TH ratios intrinsically associated 641 
with these treatments (9, 10, 15-17). Interestingly, it has been reported that the MMF 642 
treatment promotes neutropenia in some tissue-transplanted patients (45-47). Based on the 643 
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present results, it would be interesting to verify whether this collateral effect could be 644 
caused by a similar mechanism to the one described here. It would be also worth pursuing a 645 
better understanding of the proapoptotic effect of MMF on neutrophils. Given that this 646 
effect is only observed in an AngII- and AT1 receptor-dependent manner, we surmise that 647 
MMF must create some metabolic imbalance in stimulated neutrophils. Whether this is 648 
done via in-target (inhibition of inosine monophosphate dehydrogenase) or off-target 649 
effects of the drug, remains to be determined. Effects of MMF in non lymphoid cells have 650 
been previously described (39). 651 
Interestingly, we have observed that the lack of tissue fibrosis found in TKO and 652 
Vav1–/– mice is always associated with the development of milder hypertensive states 653 
during AngII-driven hypertension conditions (Fig. 9L). Our interpretation is that this latter 654 
effect is a downstream consequence of the lack of fibrosis and the subsequent preservation 655 
of normal renal functions in these mice. However, given the highly intertwined connections 656 
between these two pathophysiological programs, it could be also argued that the mild 657 
hypertensive conditions are in fact responsible for the antifibrotic protection exhibited by 658 
these two mouse strains. Although it is difficult to formally exclude this possibility at the 659 
experimental level, we do not believe this alternative scenario is possible because: (i) We 660 
have observed that the arterial blood pressure of AngII-infused WT and Vav1–/– mice is 661 
rather similar during the early phases of the AngII infusion (0 to six weeks) and only 662 
become statistically different upon the long-term exposure of animals to this vasopressor 663 
(10-15 weeks). Thus, from a kinetic point of view, it does not seem that the differential 664 
hypertension values could be the original cause of the lack of fibrosis in Vav1-deficient 665 
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mice. (ii) We have found that the overall blood pressure levels shown by AngII-infused 666 
Vav1–/– and TKO mice are similar to those present in animals that do develop a full fibrotic 667 
response (i.e., untreated DKO mice). Consistent with this, we also have found that TKO 668 
(both untreated and AngII-treated) and Vav1–/– (AngII treated) mice do develop other 669 
hypertension-associated dysfunctions such as, for example, the thickening of the arterial 670 
media wall. (iii) We have seen that the time of divergence of blood pressure values between 671 
AngII-infused WT and Vav1–/– mice matches the time when the controls have already 672 
developed cardiorenal fibrosis (Fig. 2H), thus suggesting that the milder hypertension 673 
shown by untreated TKO, AngII-treated TKO, and AngII-infused Vav1–/– mice could be an 674 
effect derived from the lack of fibrosis development in these animals. This could originate 675 
from either a direct pressor effect of the lack of fibrosis or by the collateral engagement of 676 
other hypertension-linked processes that contribute to the pressure-natriuresis mechanism 677 
involved in long-term pressure control (i.e., production of aldosterone and vasopressin) 678 
(48). Regardless of the initial cause of the event, it is clear that the renal dysfunctions and 679 
the hypertensive state will eventually collaborate in a mutually reinforcing loop to 680 
ultimately determine the final arterial pressure and fibrosis state found in each of the 681 
control and test strains analyzed in the present study. 682 
Outside the cardiovascular field, this work has also given information about the role 683 
of Vav proteins in lymphocyte subpopulations and neutrophils. Thus, we have observed 684 
that Vav proteins seem to be dispensable for both TREG cell development and effector 685 
functions at least in the pathophysiological context studied in this work. This is in sharp 686 
contrast to the critical roles played by these proteins during the stepwise development, 687 
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selection, and final effector stages of conventional CD4+ and CD8+ T cells (27, 28). Given 688 
that TREG cells require low T cell receptor signals to undergo effective positive selection 689 
(49), this result suggests that Vav proteins probably contribute to establish optimal 690 
thresholds of T cell receptor signaling during the intrathymic selection process rather being 691 
involved in yes/no digital decisions. The increased TREG/TH cell ratios present in these mice 692 
may also explain the lack of autoimmunity present in Vav family deficient mice despite 693 
their defects in negative selection (50). Such property is specific for Vav proteins, because 694 
the elimination of other proximal T cell receptor signaling elements such as Zap70 and Lat 695 
does block TREG cell development in the thymus (51, 52). We have also seen that the lack of 696 
Vav1 does not seem to significantly affect the overall functionality of neutrophils. 697 
Consistent with this, we have observed that the renal neutropenia found in these mice can 698 
be restored upon the immunodepletion of iTREG cells. Conversely, a similar neutropenic 699 
effect can be induced when WT mice are injected with iTREG cells. Additional experiments 700 
have also revealed that the AngII-stimulation of neutrophil migration and ROS production 701 
is Vav1-independent (SF, unpublished data). These data are in agreement with previous 702 
results from H. Welch’ lab indicating no major defects in the in vivo biological properties 703 
of Vav1–/– neutrophils (53, 54). It would be important, in any case, to continue the analyses 704 
of Vav1–/– TREG cells and neutrophils to assess whether this protein plays some catalysis-705 
dependent or independent roles in any of these cell types.  706 
Taken together, these results provide a new biological perspective to understand the 707 
early steps involved in the ontogeny of cardiorenal fibrosis, one of the most fatal 708 
comorbidities associated with essential hypertension (5, 6). Given that other fibrotic- or 709 
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TREG cell -dependent diseases in liver, lung, and muscle are influenced by AngII (8, 37), it 710 
would be interesting to investigate whether the TREG cell/neutrophil axis reported here could 711 
also play protective roles against those conditions. 712 
713 
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TABLE 1. Percentage of hematopoietic subpopulations in mice of indicated genotypes. 905 
 906 










CD11b+Gr1+ neutrophils 0.37±0.07 0.91±0.17* 0.1±0.03*,† 0.15±0.01*,† 
CD4+ T cells 0.14±0.02a 0.13±0.01 0.02±0.005*,† 0.02±0.000*,† 
CD4+Foxp3+ TREG cells 0.06±0.03 0.07±0.02 0.02±0.003 0.01±0.002 
CD11b+F4/80+ macrophages  0.69±0.16 0.73±0.11 0.45±0.07 ND 
CD11c+ dendritic cells 0.26±0.04 0.26±0.04 0.3±0.03 ND 
CD11c– dendritic cells  0.16±0.04 0.17±0.05 0.14±0.03 ND 
CD8+ T cells 0.60±0.06 0.68±0.047 0.643±0.031 ND 
B220+ B cells 18.80±1.09 18.98±1.75 18.467±2.17 ND 
Blood 
CD11b+Gr1+ neutrophils 18.30±2.6 48.20±2.60* 46.3±7*,† 12.1±1.3 
CD4+ T cells 22.08±2.11 29.24±3.10 7.43±0.14*,† 5.73±0.21*,† 
CD4+Foxp3+ TREG cells 1.22±0.21 2.46±0.36 1.63 1.35±0.04 
CD8+ T cells 16.07±0.91 7.67±1.94 4.03±1.35*,† 6.09±0.72*,† 
B220+ B cells 29.25±9.33 12.24±3.65* 7.92±2.01* 7.34±2.96* 
Spleen 
CD4+ T cells 10.07±0.48 12.17±1.67 3.77±0.44*,† 4.35±0.32*,† 
CD4+Foxp3+ TREG cells 1.04±0.065 0.95±0.02 0.91±0.02 1.11±0.079 
CD8+ T cells 10.60±0.69 8.52±0.37 3.43±0.49*,† 3.41±0.17*,† 
B220+ B cells 70.25±1.19 71.4±1.9 33.7±2.84*,† 26.2±3.08*,† 
Thymus 
CD4+CD8– T cells 9.71±0.53 9.34±0.64 2.77±0.25*,† 5.21±1.07*,† 
CD4+Foxp3+ TREG cells 0.49±0.04 0.39±0.06 0.29±0.06 0.6±0.18 
CD4–CD8+ T cells 6.57±2.03 2.93±0.32 1.8±0.19*,† 3.39±0.68*,† 
CD4+CD8+ thymocytes 75.3±1.96 80.5±1 40.23±1.52*,† 59.3±5.57*,† 
CD4–CD8– thymocytes 8.24±0.86 7.24±0.3 55.17±1.52*,† 31.6±5.16*,† 
a Percentage (in %) of indicated cells in the total population analyzed were measured by 907 
flow cytometry as indicated in Experimental Procedures. Statistically significant 908 
variations are shown using red bold type. * and †, P ≤ 0.05 relative to WT and DKO mice, 909 
respectively (n = 6 mice/genotype). ND, not determined. 910 
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FIGURE 1. Vav family TKO mice show protection against heart hypertrophy and 913 
cardiorenal fibrosis. (A) Mean arterial pressure evolution in indicated mice. *, P ≤ 0.05; 914 
***, P ≤ 0.001 (n = 8). (B) Examples of aorta (left panels), heart ventricles (second panels 915 
from left), left ventricle (third panels from left) and kidney (right panels) sections obtained 916 
from four-month-old mice of indicated genotypes (left). Sections were stained as indicated 917 
(bottom). Sirius-red-stained fibrotic deposits in interstitial areas are seen as dark pink areas 918 
(fourth panel from left). amw, aorta media wall; lv, left ventricle; rv, right ventricle. Scale 919 
bars, 100 µm. Similar results were obtained using serial sections and independent mice (n = 920 
4). (C to F) Status of cardiovascular (C and D) and cardiorenal (E and F) parameters in 921 
mice of indicated genotypes. LV, left ventricle. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 922 
relative to either control or indicated experimental pair (in brackets) (n = 4). (G) Example 923 
of kidney sections from mice of indicated genotypes (top). WT mice exhibit normal 924 
glomeruli (g) and tubules (t) whereas DKO animals display typical signs of glomerular 925 
sclerosis, cytoplasmic vacuolar accumulation (v) in necrotic tubules, and protein casts (c). 926 
Erithrocytes (e) are seen as red spots in all sections. Scale bars, 50 µm. (H to J) Daily urine 927 
production (H, n = 6), urine protein content (I, n = 6), and creatinine clearance rates (J, n = 928 
4) in mice of indicated genotypes. *, P ≤ 0.05 relative to either control or indicated 929 
experimental pair (in brackets). (K) Levels of Lcn2 transcript in kidneys of indicated 930 
animals. *, P ≤ 0.05 relative to either control or indicated experimental pair (in brackets) (n 931 
= 4). (L to N) Area under the curve (a.u.c.) values (L) and renal parameters (M and N) in 932 
mice of indicated genotypes after being infused with (+) or without (–) AngII. *, P ≤ 0.05; 933 
**, P ≤ 0.01; ***, P ≤ 0.001 relative to either control or indicated experimental pairs (in 934 
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brackets) (n = 4). NS, not statistically significant. Error bars in panels of this figure and 935 
subsequent ones represent the S.E.M. 936 
937 
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FIGURE 2. The Vav1 gene deficiency protects against AngII-triggered cardiorenal 941 
dysfunctions. (A to E) Status of indicated cardiovascular (A to C) and renal (D and E) 942 
parameters in mice of indicated genotypes after being infused with (+) or without (–) 943 
AngII. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (n = 10). (F and G) Mean arterial pressure 944 
evolution (F) and a.u.c. values (G) in indicated mouse strains and treatments. *, P ≤ 0.05; 945 
***, P ≤ 0.001 (n = 6). (H) Kinetics of cardiorenal fibrosis development in AngII-treated 946 
WT mice. *, P ≤ 0.05 (n = 4). (I and J) Evolution (I) and a.u.c. (J) of mean arterial pressure 947 
in mice of indicated genotypes in the presence or absence of L-NAME. ***, P ≤ 0.001 (n = 948 
4). (K to N) Status of indicated vascular (K), heart (L,M) and renal (N) parameters in WT 949 
and Vav1–/– mice at the end of L-NAME treatments. Please note that, unlike the case of 950 
AngII infusion, the oral administration of L-NAME does not induce aorta remodeling even 951 
in WT mice (K). *, P ≤ 0.05; ***, P ≤ 0.001 (n = 4). Statistical values are given relative to 952 
either untreated WT controls or indicated experimental pairs (in brackets). 953 
954 









FIGURE 3. MMF protects immunodeficient mice against cardiorenal fibrosis. (A to B) 962 
Cardiorenal fibrosis (A and B) and a.u.c. blood pressure levels (C) developed by Foxn1nu 963 
mice after a 14-day-long treatment with indicated agents (bottom) *, P ≤ 0.05; **, P ≤ 0.01; 964 
***, P ≤ 0.001 relative to either control or indicated experimental pairs (in brackets) (n = 965 
6). 966 
967 
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 968 
FIGURE 4. Increased TREG/TH cell percentages protect against AngII-triggered cardiorenal 969 
fibrosis. (A) Example of purified iTREG cells used in these experiments. CD4+ cells obtained 970 
from homogenized spleens and separated by flow cytometry (two left panels) were cultured 971 
with antibodies to CD3 and CD28, interleukin 2 and transforming growth factor β1. After 972 
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four days, CD25 expression was checked by flow cytometry (third panel from left) and 973 
injected into mice.  Aliquots of cells were in some cases checked for Foxp3 expression 974 
(right). (B) Ratio of indicated cell populations in kidneys from animals that, upon injection 975 
of 2 x 105 Lyt.1+ TREG cells, were infused 24 hours later with AngII for the indicated periods 976 
of time. (C) Mean number of indicated cell populations found in kidneys from mice used in 977 
panel B (n = 4). (D to F) Cardiorenal fibrosis (D and E) and a.u.c. mean arterial pressure 978 
levels (F) present in WT mice that had been maintained under the indicated conditions for 979 
14 days, *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to either control or indicated 980 
experimental pairs (in brackets) (n = 4). (G and H) Representative example (G) and 981 
quantification (H) of kidney-resident neutrophils in kidneys from WT mice at the end of the 982 
above experiments. **, P ≤ 0.01 relative to either control or indicated experimental pairs 983 
(in brackets) (n = 4). (I) Quantification of kidney-resident neutrophils present in WT mice 984 
under the indicated treatments. *, P ≤ 0.05 (n = 4). (J) Percentage of iTREG cells generated 985 
from splenic WT and Vav1–/– CD4+CD25– T cells in cell culture (n = 4). (K) Extent of 986 
kidney fibrosis in AngII-infused Foxn1nu mice injected with the indicated iTREG cells as 987 
shown in insets. *, P ≤ 0.05; **, P ≤ 0.01 relative to either control or indicated 988 
experimental pairs (in brackets) (n = 4). 989 
990 
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 991 
FIGURE 5. The immunodepletion of TREG cells restores renal fibrosis in Vav1-deficient 992 
mice. (A) Evolution of the CD4+CD25+ cell population in Vav1–/– mice upon 993 
immunodepletion with antibodies to CD25. Values are given relative to cell percentages 994 
present in the same experimental time point in mice injected with a control antibody. The 995 
time of injection (t0) is indicated with an arrow. ***, P ≤ 0.001 (n = 4). (B to D) 996 
Cardiorenal fibrosis (B and C) and a.u.c. mean arterial pressure levels (D) in Vav1–/– mice 997 
subjected to indicated experimental conditions. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 998 
relative to either control or indicated experimental pairs (in brackets) (n = 4). (E and F) 999 
Representative example (E) and quantification (F) of neutrophil numbers present in kidneys 1000 
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from Vav1–/– mice used in above experiments. **, P ≤ 0.01; relative to either control or 1001 
indicated experimental pair (in brackets) (n = 4). (G) Quantification of kidney-resident 1002 
neutrophils in Vav1–/– mice under indicated conditions. *, P ≤ 0.05 (n = 4).  1003 
1004 
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 1005 
FIGURE 6. Neutrophils are involved in AngII-driven cardiorenal fibrosis. (A) Impact of 1006 
the immunodepletion step in the neutrophil numbers present in WT mice. Values are given 1007 
relative to numbers obtained in mice treated with a control antibody. ***, P ≤ 0.001 (n = 4). 1008 
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The time points of antibody and implantation of osmotic pumps are indicated by arrows. (B 1009 
and C) Extent of cardiorenal fibrosis obtained in WT animals injected with either control or 1010 
anti-Ly6G antibodies and, subsequently, infused with AngII as indicated. *, P ≤ 0.05 1011 
relative to either control or indicated experimental pairs (in brackets) (n = 4). (D) a.u.c. 1012 
values of mean arterial pressure increase obtained in the above experiment. *, P ≤ 0.05; 1013 
***, P ≤ 0.001 relative to either control or indicated experimental pairs (in brackets) (n = 1014 
4). (E and F) Quantification of kidney-resident macrophages (E) and CD4+ T cells (F) at 1015 
the end of the above experiments. (G and H) Representative dot-plots (G) and 1016 
quantification (H) of neutrophil numbers present in kidneys at the end of the above 1017 
experiments. **, P ≤ 0.01 relative to either control or indicated experimental pair (in 1018 
brackets) (n = 4). 1019 
1020 
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 1021 
FIGURE 7. TREG cells protect against hypertension-driven fibrosis in an 1022 
immunosuppression-independent manner. (A to E) Renal fibrosis (A and D), kidney 1023 
abundance of Lcn2 transcripts (B), and a.u.c mean arterial pressure levels (C and E) in 1024 
indicated mouse strains and treatment conditions.  *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 1025 
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relative to either control or indicated experimental pairs (in brackets) (n = 4). (F and G) 1026 
Representative dot-plots (F) and quantification (G) of kidney-resident neutrophils in mouse 1027 
strains and treatment conditions. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 relative to either 1028 
control or indicated experimental pairs (in brackets) (n = 4). (H and I) Number of kidney-1029 
resident and circulating neutrophils present in Foxn1nu mice under indicated experimental 1030 
conditions. *, P ≤ 0.05 relative to control (n = 4).  1031 
1032 
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FIGURE 8. TREG cells induce CD39-dependent neutrophil apoptosis. (A) Example of the 1035 
flow cytometry purification step to obtain splenic CD4+CD25+ nTREG cells used in 1036 
experiments shown in this figure. (B and C) Apoptotic response (A) and ROS production 1037 
(B) of neutrophils under indicated in vitro conditions. ARL, ARL67156; CD4+, 1038 
CD4+CD25– T cells; CD8+, CD8+ T cells; CD39+, CD4+CD25+CD39+ nTREG cells; CD39–, 1039 
CD4+CD25+CD39– nTREG cells; Los, losartan; PD, PD123319. *, P ≤ 0.05; **, P ≤ 0.01; 1040 
***, P ≤ 0.001 relative to either control or indicated experimental pairs (in brackets) (n = 1041 
4). (D) Effect of TREG cell-derived culture supernatants on neutrophil chemotaxis (values 1042 
obtained with media alone were given an arbitrary value of 1). *, P ≤ 0.05 relative to 1043 
control (n = 4). (E) Example of the purification step used to obtain splenic CD39+ and 1044 
CD39– nTREG cells used in this figure. (F to H) Apoptotic response of neutrophils under 1045 
indicated culturing conditions. α-CD3 and α-CD28, antibodies to mouse CD3 and CD28, 1046 
respectively. **, P ≤ 0.01; ***, P ≤ 0.001 relative to either control or indicated 1047 
experimental pairs (in brackets) (n = 4). (I) AngII-stimulated ROS production of 1048 
neutrophils under indicated culturing conditions. **, P ≤ 0.01 relative to control (n = 4). 1049 
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FIGURE 9. CD39+ TREG cells are involved in the protection against AngII-driven 1053 
cardiorenal dysfunctions. (A) Example of the flow cytometry-mediated purification of 1054 
CD39+ and CD39– iTREG cells used in these experiments.  (B to E) Percentage of kidney-1055 
infiltrating neutrophils (B), extent of cardiorenal fibrosis (C and D), and blood pressure 1056 
levels (E) in WT mice under indicated experimental conditions. *, P ≤ 0.05; **, P ≤ 0.01; 1057 
***, P ≤ 0.001 relative to either control or indicated experimental pairs (in brackets) (n = 1058 
4). (F to K) Percentage of kidney-infiltrating neutrophils (F, n = 4), cardiorenal fibrosis (G 1059 
and H, n = 4), abundance of Lnc2 transcripts in kidney (I, n = 4), creatinine clearance rates 1060 
(J, n = 6), and overall blood pressure levels (K, n = 4) in indicated mice and experimental 1061 
conditions. *, P ≤ 0.05; **, P ≤ 0.05; ***, P ≤ 0.001 relative to either control or indicated 1062 
experimental pairs (in brackets). (L) The new mechanism (green) described in this work. 1063 
Inhibitors tested exclusively in vitro and in vivo are in red and blue color, respectively. 1064 
Those used in both conditions are in light brown. The TREG-TH-neutrophil connection is 1065 
proposed based on previously published data. RAS, renin-angiotensin system. 1066 
